90%Confidence
0Views
FDASource
2026-03-05Date
Summary
Vancomycin sterility failure represents the third compounding issue for Fresenius Kabi, indicating serious systemic quality control deficiencies. This could trigger broader FDA investigations into their entire compounding operation.
Actionable: Evaluate Fresenius Kabi's risk management practices and consider reducing exposure until they resolve these compounding facility issues.
AI Confidence: 90%
Data Points
firmFresenius Kabi Compounding, LLC
classificationClass II
statusOngoing
distributionUS Nationwide.
productvancomycin HCl, 1.5 grams, 1.5 grams added to 500 mL, 0.9% Sodium Chloride Injection, USP, Fagron Sterile Services, 20 Dan Road, Canton, MA 02021, NDC
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now